ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0789

An Online Trial to Assess the Efficacy and Safety of a Supplement Combination in People with Hand Osteoarthritis

Xiaoqian Liu1, Sarah Robbins1, Jillian Eyles1, Leticia Deveza1, Andrew McLachlan1 and David Hunter2, 1The University of Sydney, Sydney, New South Wales, Australia, 2Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia

Meeting: ACR Convergence 2024

Keywords: Osteoarthritis, pain

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Abstracts: Osteoarthritis – Clinical Trials

Session Type: Abstract Session

Session Time: 1:00PM-2:30PM

Background/Purpose: Hand osteoarthritis is a debilitating and highly prevalent disease with limited treatment options. The aim of this study was to investigate the efficacy and safety of a newly developed combined supplement in people with hand osteoarthritis (OA).

Methods: This was an internet-based, double-blind, randomised, placebo-controlled trial without face-to-face interaction between investigators and participants. The main eligibility criteria were aged over 40 years with symptomatic hand OA and Kellgren Lawrence grade (KLG) 2 and above. The recruitment was conducted across Australia. Eligible participants were randomly assigned to receive either a combined supplement or placebo (1:1) for 12 weeks. The active ingredients in the combined supplement were Boswellia serrata extract 250 mg/day, pine bark extract 100 mg/day, methylsulfonylmethane 1,500 mg/day and curcumin 168 mg/day. The primary outcome was change in hand pain assessed using a visual analogue scale (VAS, 0-100) from baseline to week 12. Secondary outcomes included change in functional Index of Hand Osteoarthritis, patient global assessment and health-related quality of life. Adverse events were monitored weekly.

Results: We included a total of 106 participants with a mean age of 65.6 years and 81% female. The majority of the participants were moderate to severe on the radiographic assessment, with 40% KLG 3 and 45% KLG 4, and 37% participants had erosive OA. Pain VAS decreased over 12 weeks in both active and placebo groups with mean change (95%CI) -8.64 (-14.35 to -2.92, p=0.004) and -14.63 (-20.94 to -8.32, p < 0.001), respectively. The adjusted between-group difference over 12 weeks was 5.34 (95%CI, -2.39 to 13.07, p=0.17). Five participants (10%) in the supplement combination group discontinued study treatment due to AE vs four participants (7%) in the placebo group.

Conclusion: Treatment with the supplement combination was not superior to treatment with a placebo for improving hand pain over 12 weeks. Results do not support the initiation of supplement combination therapy for people with moderate- to late-stage- hand OA.

Supporting image 1

Flowchart of the trial profile

Supporting image 2

Comparison between supplement combination and placebo on change in clinical symptoms

Supporting image 3

Change in primary and secondary outcomes over 12 weeks between supplement combination and placebo groups


Disclosures: X. Liu: None; S. Robbins: None; J. Eyles: None; L. Deveza: None; A. McLachlan: None; D. Hunter: Novartis, 2, TLC, 2.

To cite this abstract in AMA style:

Liu X, Robbins S, Eyles J, Deveza L, McLachlan A, Hunter D. An Online Trial to Assess the Efficacy and Safety of a Supplement Combination in People with Hand Osteoarthritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/an-online-trial-to-assess-the-efficacy-and-safety-of-a-supplement-combination-in-people-with-hand-osteoarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/an-online-trial-to-assess-the-efficacy-and-safety-of-a-supplement-combination-in-people-with-hand-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology